Posted: Jan. 28, 2014
In view of an emerging consensus on how Alzheimer’s disease develops and progresses, the Cure Alzheimer’s Fund Research Consortium aggressively is focusing on three opportunities for possible intervention—at the early stage of the disease, the middle stage and the late stage. This comprehensive strategy addresses the whole picture of how Alzheimer’s disease develops and progresses, and attacks all three points simultaneously.
Posted: Oct. 4, 2013
"Desperate For A Cure: The Search For New Alzheimer's Treatments", a new five-part series by NPR's Sean Corcoran, aired this week on WCAI and will air again next week on WGBH in Boston.
Posted: Sep. 19, 2013
Drs. Sam Gandy and Scott Noggle have received an NIH grant to gain new insights and identify potential therapies for Alzheimer’s disease.
Posted: Jul. 29, 2013
For several years now, researchers have been aware of important links between cholesterol and Alzheimer's disease. A new study by Dr. Dora Kovacs and her team at Massachusetts General Hospital brings us one step closer to a potential drug that could interrupt the disease process.
Posted: May 24, 2013
While many were anxious to accept initial findings showing a drug known as Targretin’s “too good to be true” lab results with Alzheimer’s disease, subsequent attempts to confirm and replicate the original data regarding the ability of Targretin to remove amyloid plaques, the cardinal lesion of the disease, have largely failed. Cure Alzheimer’s Fund Research Consortium members Dr. Sangram Sisodia, professor of neuroscience at the University of Chicago and Dr.
Posted: Apr. 25, 2013
BOSTON— Excessive levels of the protein CD33 can impede the clearance of the plaque-forming protein, amyloid beta, the key component of senile plaques in the brains of Alzheimer’s disease patients. The discovery, made by Dr. Rudolph Tanzi and colleagues at Massachusetts General Hospital, and co-funded by the Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) will be published in the journal Neuron.
Posted: Oct. 9, 2012
October 9 -- Eli Lilly announced encouraging results yesterday involving their experimental drug Solanezumab. Solanezumab is an antibody aimed at lowering beta-amyloid levels in the brain. In trials lasting 18 months, patients with mild Alzheimer's symptoms taking Solanezumab showed significantly less cognitive decline -- 34% less -- compared with patients taking the placebo.
Posted: Apr. 24, 2012
Cure Alzheimer’s Fund has received many questions about the value of coconut oil in combatting Alzheimer’s. We’ve asked Rudy Tanzi, Ph.D., to respond to these inquiries generically, knowing that a) there is currently no peer-reviewed clinical research available regarding efficacy of coconut oil in treating or preventing Alzheimer’s, and b) every personal situation and experience is unique. Rudy has agreed to provide his perspective on this, given those two giant caveats.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.